The menopausal transition may be a challenging period in a woman's life. For some, the menopausal symptoms may last for many years and can result in significant physical and emotional consequences. Adverse publicity regarding hormone replacement therapy (HRT) use over the last decade has resulted in a significant decline in HRT use, and as a result many women have been left to cope with their menopausal symptoms. This article discusses the current evidence on the role of HRT in the management of menopausal women, including its benefits and potential risks. It also summarises the recent HRT guidelines published by the British Menopause Society.
Get full access to this article
View all access options for this article.
References
1.
BagotC. N.MarshM. S.WhiteheadM.SherwoodR.RobertsL.PatelR. K.AryaR. (2010) The effect of estrone on thrombin generation may explain the different thrombotic risk between oral and transdermal hormone replacement therapy. Journal of Thrombosis and Haemostasis8(8): 17361744. doi: 10.1111/j.1538-7836.2010.03953.x.
2.
BrombergerJ. T.SchottL. L.KravitzH. M.SowersM.AvisN. E.GoldE. B.MatthewsK. A. (2010) Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: Results from the Study of Women's Health Across the Nation (SWAN). Archives of General Psychiatry67: 598607. doi: 10.1001/archgenpsychiatry.2010.55.
3.
CirilloD. J.WallaceR. B.WuL.YoodR. A. (2006) Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. Arthritis & Rheumatism54: 31943204. doi: 10.1002/art.22138.
4.
Cody, J. D., Richardson, K., Moehrer, B., Hextall, A., & Glazener, C. M. A. (2009). Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database of Systematic Reviews, 4, art. no.: CD001405. doi: 10.1002/14651858.CD001405.pub2.
5.
DavisS. R.MoreauM.KrollR.BouchardC.PanayN.GassM.StuddJ. (2008) For the APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. New England Journal of Medicine359: 20052017. doi: 10.1056/NEJMoa0707302.
6.
De VilliersT. J.GassM. L. S.HainesC. J.HallJ. E.LoboR. A.PierrozD. D.ReesM. (2013) Global consensus statement on menopausal hormone therapy. Climacteric16: 203204. doi: 10.3109/13697137.2013.771520.
7.
FournierA.FabreA.MesrineS.Boutron-RuaultM. C.BerrinoF.Clavel-ChapelonF. (2008) Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. Journal of Clinical Oncology26: 12601268. doi: 10.1200/JCO.2007.13.4338.
8.
Harman, S. M. (2012). Effects of oral conjugated estrogen or transdermal estradiol plus oral progesterone treatment on common carotid artery intima media thickness (CIMT) & coronary artery calcium (CAC) in menopausal women: Initial results from the Kronos Early Estrogen Prevention Study (KEEPS). Presented at The North American Menopause Society Meeting 2012. Retrieved from www.menopause.org/docs/professional/speaker-abstracts.pdf?sfvrsn=0.
9.
Lethaby, A., Hogervorst, E., Richards, M., Yesufu, A., & Yaffe, K. (2008). Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database of Systematic Reviews, 1, art. no.: CD003122. doi: 10.1002/14651858.CD003122.pub2.
10.
L’ HermiteM. (2013) HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric16(S1): 4453. doi: 10.3109/13697137.2013.808563.
11.
LindsayR.GallagherJ. C.KleerekoperM.PickarJ. H. (2002) Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. Journal of the American Medical Association287: 26682676.
12.
MacLennan, A. H., Broadbent, J. L., Lester, S., & Moore, V. (2004). Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews 4, art. no.: CD002978. doi: 10.1002/14651858.CD002978.pub2.
13.
MiddletonE. T.SteelS. A. (2007) The effects of short-term hormone replacement therapy on long-term bone mineral density. Climacteric10(3): 257263.
14.
PanayN.Al-AzzawiF.BouchardC.DavisS. R.EdenJ.LodhiI.SturdeeD. W. (2010) Testosterone treatment of HSDD in naturally menopausal women: The ADORE study. Climacteric13: 121131. doi: 10.3109/13697131003675922.
15.
PanayN.HamodaH.AryaR.SavvasM. (2013) The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy. Menopause International19(2): 5968. doi: 10.1177/1754045313489645.
16.
PanayN.KaluE. (2009) Management of premature ovarian failure. Best Practice & Research Clinical Obstetrics and Gynaecology23: 129140.
17.
PrestwoodK. M.KennyA. M.KleppingerA.KulldorffM. (2003) Ultra low dose micronized 17A-estradiol and bone density and bone metabolism in older women: A randomized controlled trial. Journal of the American Medical Association290: 10421048.
RenouxC.Dell'anielloS.SuissaS. (2010) Hormone replacement therapy and the risk of venous thromboembolism: A population-based study. Journal of Thrombosis and Haemostasis8: 979986. doi: 10.1111/j.1538-7836.2010.03839.
21.
SchierbeckL. L.RejnmarkL.ToftengC. L.StilgrenL.EikenP.MosekildeL.JensenJ. E. (2012) Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: Randomized trial. British Medical Journal345: e6409doi: 10.1136/bmj.e6409.
22.
SchmidtP. (2012) The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause: The Journal of the North American Menopause Society19(3): 257271.
23.
ShumakerS. A.LegaultC.KullerL.RappS. R.ThalL.LaneD. S.CokerL. H. (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. The Journal of the American Medical Association291: 29472958. doi: 10.1001/jama.291.24.2947.
24.
SimonJ. A. (2012) What's new in hormone replacement therapy: Focus on transdermal estradiol and micronized progesterone. Climacteric15(S1): 310. doi: 10.3109/13697137.2012.669332.
25.
Somboonporn, W., Bell, R. J., & Davis, S. R. (2005). Testosterone for peri and postmenopausal women. Cochrane Database of Systematic Reviews, 4, art. no.: CD004509. doi: 10.1002/14651858.CD004509.pub2.
26.
StevensonJ. C. (2006) International Consensus Group on HRT and Regulatory Issues. HRT, osteoporosis and regulatory authorities Quis custodiet ipsos custodes?Human Reproduction21: 16681671. doi: 10.1093/humrep/del043.
27.
SturdeeD. W.PanayN. (2010) On behalf of the International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric13: 509522. doi: 10.3109/13697137.2010.522875.
28.
SturdeeD. W.PinesA. (2011) On behalf of the Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric14: 302320. doi: 10.3109/13697137.2011.570590.
29.
WHO. (2013). The FRAX® fracture risk assessment tool. Retrieved from www.shef.ac.uk/FRAX.
30.
Writing Group for the Postmenopausal Estrogen/Progestin Interventions Trial. (1996) Effects of hormone therapy on bone mineral density: Results from the PEPI trial. Journal of the American Medical Association276: 13891396.
31.
Writing Group for the Women's Health Initiative Investigators. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomised controlled trial. The Journal of the American Medical Association288: 321333. doi:10.1001/jama.288.3.321.
